Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
840 stopped studies mapped to Malignant Prostate Neoplasm and descendants · 92% state a reason
Over the 840 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation… | Phase 1 / Phase 2 | suspended | Aug 28, 2019 | National Cancer Institute (NCI) | Other - To assess the study's feasibility. | Other (stated, no rule matched) |
| NCT06144619 | Non-Invasive Biomarkers in Prostate Cancer Disease Management | — | suspended | Nov 22, 2023 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | Phase 1 | terminated | Nov 4, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT04808427 | Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate… | N/A | suspended | Mar 22, 2021 | National Cancer Institute (NCI) | On hold pending consideration of an amendment to increase recruitment. | Enrollment / accrual |
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | — | withdrawn | Feb 27, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT03694483 | Prostasomes as Diagnostic Tool for Prostate Cancer Detection | — | suspended | Oct 3, 2018 | Hackensack Meridian Health | Staffing changes, pending funding renewal | Funding |
| NCT05700903 | Contributions to Hypertension With Androgen Deprivation Therapy(ARCH) | Phase 4 | terminated | Jan 26, 2023 | University of Colorado, Denver | Study completed | Other (stated, no rule matched) |
| NCT06804785 | Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer…(HIT-PIRADS) | — | withdrawn | Feb 3, 2025 | Northwestern University | Due to funding issues the study did not move forward with prospective enrollment | Enrollment / accrual |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… | Phase 1 | withdrawn | May 21, 2025 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic… | Phase 2 | terminated | Feb 22, 2018 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer… | Phase 1 / Phase 2 | terminated | Nov 17, 2020 | Amgen | Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not… | Safety / toxicity |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | Memorial Sloan Kettering Cancer Center | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT06200103 | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate… | Phase 2 | suspended | Jan 10, 2024 | Mayo Clinic | Pending additional funding. | Funding |
| NCT00126230 | Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer | Phase 2 | terminated | Aug 3, 2005 | Gustave Roussy, Cancer Campus, Grand Paris | not stated | Not stated |
| NCT07102212 | Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding…(FOCUS) | N/A | suspended | Aug 3, 2025 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… | Phase 1 / Phase 2 | terminated | May 12, 2016 | National Cancer Institute (NCI) | Accrual and drug manufacturing and supply were discontinued in 2025. | Drug supply |
| NCT04519879 | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or… | Phase 2 | suspended | Aug 20, 2020 | City of Hope Medical Center | 05/26/2026 DSMC: Delinquent PMT reporting. | Other (stated, no rule matched) |
| NCT05995236 | Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy | — | terminated | Aug 16, 2023 | Methodist Health System | So far, we have not been able to collect meaningful data for these patients which also led to our… | Other (stated, no rule matched) |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Phase 2 | terminated | May 15, 2017 | Wake Forest University Health Sciences | PIs not interested in continuing with the trial. | Other (stated, no rule matched) |
| NCT04646434 | Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing… | N/A | suspended | Nov 30, 2020 | Roswell Park Cancer Institute | Protocol being updates and staff trained | Other (stated, no rule matched) |
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome(PRIME) | Phase 3 | terminated | Jan 26, 2017 | Canadian Urologic Oncology Group | Manufacturer discontinued the production of study drugs. | Drug supply |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT06509919 | Application of a Novel Model Based on Plasma cfDNA Assay and MRl Imaging in the Detection… | — | suspended | Jul 19, 2024 | Shanghai Changzheng Hospital | Modifications to trial design | Other (stated, no rule matched) |
| NCT00788307 | Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate… | Phase 1 | terminated | Nov 10, 2008 | Mayo Clinic | closed early due to poor accrual | Enrollment / accrual |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate… | Phase 2 | terminated | Jan 18, 2023 | Mayo Clinic | Sponsor decided to close due to slow accrual and lack of efficacy | Efficacy / futility |
| NCT06226129 | Gadopiclenol in Contrast Enhanced MRI of the Prostate | Phase 4 | suspended | Jan 26, 2024 | Columbia University | The study is being transferred to another institution | Other (stated, no rule matched) |
| NCT04698564 | Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging | Phase 2 | terminated | Jan 7, 2021 | University of Maryland, Baltimore | "Study terminated due to institutional resource constraints, including limited availability of… | Safety / toxicity |
| NCT05067777 | Massage for Prostate Cancer-Related Fatigue (mPROSTATE)(mPROSTATE) | Phase 2 | terminated | Oct 5, 2021 | University of Utah | Lack of Funding | Funding |
| NCT05422105 | Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient | — | suspended | Jun 16, 2022 | Primo Biotechnology Co., Ltd | Interim Analysis | Efficacy / futility |
| NCT04887935 | Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer | Phase 1 | terminated | May 14, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT07146113 | Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive…(PRIME) | — | suspended | Aug 28, 2025 | AstraZeneca | As a part of planned reassessment for the current period, a decision has been made to prioritize,… | Enrollment / accrual |
| NCT04346225 | Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in… | Phase 2 | suspended | Apr 15, 2020 | Ivan de Kouchkovsky, MD | Due to funding | Funding |
| NCT04581109 | Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer…(EPIDROP) | N/A | terminated | Oct 9, 2020 | University Hospital, Montpellier | Flaw in the analytical technique | Other (stated, no rule matched) |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients… | Phase 1 / Phase 2 | withdrawn | May 6, 2026 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT05597878 | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy | Phase 2 / Phase 3 | terminated | Oct 28, 2022 | Wake Forest University Health Sciences | Study initially suspended following an audit and need of amendment to address deficiencies. PI… | Other (stated, no rule matched) |
| NCT04745871 | Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in…(PREOP-PSMA) | N/A | terminated | Feb 9, 2021 | University Hospital, Brest | In the PREOP-PSMA protocol, written before 68Ga-PSMA-11 obtained Marketing Authorization. Today,… | Other (stated, no rule matched) |
| NCT06185478 | Prostate Diffusion Imaging With Distortion Correction | N/A | withdrawn | Dec 29, 2023 | Norfolk and Norwich University Hospitals NHS Foundation Trust | Study abandoned due to COVID-19 (07/06/2024). | COVID-19 / pandemic |
| NCT04981834 | Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate… | N/A | suspended | Jul 29, 2021 | University of Southern California | Accrual goal reached and suspended for analysis purposes. | Enrollment / accrual |
| NCT01885949 | Tivozanib + Enzalutamide in Adv Prostate Cancer | Phase 2 | terminated | Jun 25, 2013 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT00183937 | Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Sponsor stopped study early. | Other (stated, no rule matched) |
| NCT01673581 | Shared Decision Making in Low Risk Prostate Cancer | — | withdrawn | Aug 28, 2012 | Massachusetts General Hospital | Due to unforeseen changes in study personnel, the study was not initiated. | Other (stated, no rule matched) |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients… | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Corcept Therapeutics | The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the… | Enrollment / accrual |
| NCT04565496 | Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk…(PEM-PRO) | Phase 2 | withdrawn | Sep 25, 2020 | IRCCS San Raffaele | Study related: Study terminated early due to protocol evolution from neoadjuvant to perioperative… | Enrollment / accrual |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Jan 20, 2021 | Thomas Hope | Low accrual | Enrollment / accrual |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer… | Phase 2 | terminated | Jul 24, 2019 | University of California, Davis | PI choice; poor accrual | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT07237399 | Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis…(TA-P-OLIM) | — | withdrawn | Nov 19, 2025 | University Hospital, Ghent | No funding | Funding |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone… | Phase 2 | withdrawn | Jun 17, 2025 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT05820932 | Predicting Cognitive Decline From Androgen Deprivation Therapy(ABC) | — | terminated | Apr 20, 2023 | University of California, San Francisco | Slow Accrual | Enrollment / accrual |
| NCT05362032 | Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted… | N/A | suspended | May 5, 2022 | OHSU Knight Cancer Institute | Study team paused enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials